The global cancer immunotherapy market study presents historical market data in terms of values (2016 and 2017), estimated current data (2018), and forecasts for 2024-by product (monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy), application (lung cancer, breast cancer, multiple myeloma, colorectal cancer, melanoma, prostate cancer, and other cancer types), and end user (hospitals, and clinics & others). The study also evaluates industry competitors and analyzes the market at regional and country level.

On the basis of product type, monoclonal antibodies segment commanded the largest share of the global cancer immunotherapy market in 2017. However, checkpoint inhibitors market is expected to grow at the fastest CAGR during the forecast period, owing to high success rate of PD-1 & PD-L1 drugs and increasing pipelines of biotechnology and pharmaceutical companies with combination therapies for anti-PD-1 and PD-L1 inhibitors. Moreover, cell therapy market is also expected to witness significant growth through 2024. Development of new and effective therapy options to cure symptoms of the disease is a key factor contributing to growth of cell therapy market.

Browse in-depth Report on - https://www.meticulousresearch.com/product/cancer-immunotherapy-market/

On the basis of application, cancer immunotherapy market for lung cancer application commanded the largest share of the global market in 2017. Major factors propelling the growth of cancer immunotherapy market in lung cancer application are growing incidence, mortality rate, and benefits of immunotherapy to the lung cancer patients; whereas, cancer immunotherapy market for multiple myeloma applications expected to witness the highest growth rate during the forecast period. The approval of innovative caner immunotherapy for the treatment of multiple myeloma has increased the adoption of immunotherapies in treatment of multiple myeloma. Moreover, recognizing the potential of immunotherapy in multiple myeloma, major players in immunotherapy market such as Celgene, Amgen, Janssen, and Juno Therapeutics engaged in multiple collaborations to evaluate certain drug entities for the treatment of multiple myeloma.
On the basis of end user, hospitals dominated the global market. This is mainly attributed to the rise in healthcare spending which has resulted in the increasing use of immunotherapeutic drugs in hospitals and the large number of patients being treated in hospitals for cancer immunotherapy; however, clinics and other end user markets are expected to witness a rapid growth during the forecast period with the increasing number of clinics providing cancer immunotherapy, and rising number of ongoing clinical trials for immunotherapy drugs.

Request for a sample of this research report @ - https://www.meticulousresearch.com/download-sample-report/cp_id=4690

This research report analyzes major geographies and provides comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America, and Middle East & Africa. North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and Asia Pacific. However, Asia Pacific region is expected to grow at a higher CAGR during the forecast period. Growth in this market is expected to be driven by large pool of patient population seeking the cancer treatment, increasing prevalence of cancer, aggressive investment by the major players in the market, increasing government spending on the healthcare, and increasing disposable income of the population that improved the access to cancer treatment. Furthermore, lack of stringent regulations and liberalization in Asian countries is also a key factor making Asia Pacific a lucrative market.
The major players operating in the global cancer immunotherapy market are F. Hoffmann-La Roche (Switzerland), Celgene Corporation (US), Bristol-Myers Squibb (US), Merck & Co., Inc. (US), and Amgen Inc. (US),ELI Lilly and Company (US), Janssen Global Services, LLC (US) (Johnson and Johnson), Novartis (Switzerland), Pfizer, Inc. (US), Gilead Sciences, Inc. (US), Dendreon Pharmaceuticals (US), and Bayer (Germany) among others.

Contact Info:
Khushal
Email: [email protected]
Contact Sales- +1-646-781-8004